GENOMIGON Trademark
Trademark Overview
On Monday, February 6, 2023, a trademark application was filed for GENOMIGON with the United States Patent and Trademark Office. The USPTO has given the GENOMIGON trademark a serial number of 79371640. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Monday, December 16, 2024. The GENOMIGON trademark is filed in the Pharmaceutical Products, Medical Instrument Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:
Pharmaceutical preparations and substances for the treatment of malignant tumor diseases and malignant and benign blood diseases, and infectious diseases; diagnostic preparations and materials for medical purposes; diagnostic substances for medical use; diagnostic testing materials for medical use, namely, medical diagnostic test media in the form of, strips, threads, liquids, gels, and serums, for measuring, biomarkers in malignant diseases and hereditary diseases on a genetic basis or protein basis, gene variants in hereditary diseases and malignant diseases; medical diagnostic test strips for blood analysis, urine analysis, and saliva analysis; biotechnological preparations for medical use in the nature of pharmaceutical preparations for the treatment of cancer, malignant and non-malignant blood diseases and hereditary diseases; medicine, namely, cytostatics for medical purposes, antibodies for medical purposes, antibody-drug conjugates, therapeutically modified lymphocytes, mixed h...
Medical services; medical analysis services relating to disease management, disease diagnosis services, disease prognosis; medical laboratory services for the analysis of samples taken from patients; health screening services in the field of malignant tumor diseases, benign tumor diseases, malignant blood diseases, benign blood diseases, hereditary diseases, coagulation disorders; providing medical information in the healthcare sector; medical consultations; arranging of medical treatment in the field of oncology, hematology, genetics, gene therapies, targeted therapy, cell therapies; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; all the aforesaid services relating to the fields of oncology, chemotherapy, molecular genetics, molecular medicine
Genetic testing apparatus for medical purposes; diagnostic equipment and instruments for medical purposes for the analysis of body fluids, benign and malignant tissue and blood, protein structures of tumors, genetic code of tissue and blood cells, analysis of blood cells, blood plasma and blood serum; medical apparatus for carrying-out diagnostic tests for medical purposes for cancer cells, leukemia cells, benign and malignant cells of humans and animals, genetic material; medical testing instruments for medical diagnostic purposes for blood sugar levels, cancer cells, genetic material; electromedical diagnostic instruments, namely, electromedical rehabilitative and pain management products for clinical and home use, namely, electrical nerve and muscle stimulators, ultrasonic stimulators, magnet therapy stimulators and laser therapy stimulators; radiation instruments, for medical purposes, namely, radiation therapy devices; medical radiation apparatus for medical purposes; medical appa...
Scientific analysis in the field of pharmaceuticals, and medical devices; scientific research in the field of genetics, hematology, and oncology; genetic scientific research; pharmaceutical research services; clinical research in the field of radiology, radiotherapy, surgical medicine, oncological system therapy of malignant and benign diseases, and infectious diseases; research relating to biotechnology; medical research; computer aided diagnostic testing services, namely, diagnostic services for others for scientific research purposes; design and development of medical diagnostic apparatus; design and development of medical technology; development of pharmaceutical preparations and medicines; provision of information and data relating to medical and veterinary research and development; consultancy relating to research and development in the field of therapeutics; providing scientific research information in the field of medical disorders and their treatment; laboratory testing and an...
General Information
| Serial Number | 79371640 |
| Word Mark | GENOMIGON |
| Filing Date | Monday, February 6, 2023 |
| Status | 681 - PUBLICATION/ISSUE REVIEW COMPLETE |
| Status Date | Monday, December 16, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | Tuesday, January 7, 2025 |
Trademark Statements
| Description of Mark | The mark consists of the stylized wording "GENOMIGON" in blue. On the left side of the wording are twelve orange dots lined up to form a stylized orange helix. White represents background and/or transparent areas and is not claimed as a feature of the mark. |
| Goods and Services | Pharmaceutical preparations and substances for the treatment of malignant tumor diseases and malignant and benign blood diseases, and infectious diseases; diagnostic preparations and materials for medical purposes; diagnostic substances for medical use; diagnostic testing materials for medical use, namely, medical diagnostic test media in the form of, strips, threads, liquids, gels, and serums, for measuring, biomarkers in malignant diseases and hereditary diseases on a genetic basis or protein basis, gene variants in hereditary diseases and malignant diseases; medical diagnostic test strips for blood analysis, urine analysis, and saliva analysis; biotechnological preparations for medical use in the nature of pharmaceutical preparations for the treatment of cancer, malignant and non-malignant blood diseases and hereditary diseases; medicine, namely, cytostatics for medical purposes, antibodies for medical purposes, antibody-drug conjugates, therapeutically modified lymphocytes, mixed hormone preparations, preparations for the targeted treatment of malignant and non-malignant diseases in the nature of targeted delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals that inhibit, activate or modulate regulatory cascades in malignant and non-malignant diseases or the microenvironment such as tyrosine kinase inhibitors, antibodies, antibody drug conjugates, immune checkpoint inhibitors, T cell engagers, modified effector cell preparations such as CAR-T cells, bispecific or multispecific antibodies, antibody-nuclide conjugates; biopharmaceuticals for medical purposes in the nature of pharmaceutical preparations for the treatment of, malignant blood diseases, benign blood diseases, malignant solid tumors, benign solid tumors, cancer and hereditary diseases; biopharmaceuticals for medical purposes in the nature of pharmaceutical preparations for healing or alleviating ailments and reducing symptoms of blood diseases; biological preparations for medical purposes, namely, biological preparations for the treatment of, malignant blood diseases, benign blood diseases, malignant solid tumors, and benign solid tumors; all the aforesaid goods relating to the fields of oncology, chemotherapy, molecular genetics, molecular medicine |
| Indication of Colors claimed | The color(s) orange and blue is/are claimed as a feature of the mark. |
| Goods and Services | Medical services; medical analysis services relating to disease management, disease diagnosis services, disease prognosis; medical laboratory services for the analysis of samples taken from patients; health screening services in the field of malignant tumor diseases, benign tumor diseases, malignant blood diseases, benign blood diseases, hereditary diseases, coagulation disorders; providing medical information in the healthcare sector; medical consultations; arranging of medical treatment in the field of oncology, hematology, genetics, gene therapies, targeted therapy, cell therapies; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; all the aforesaid services relating to the fields of oncology, chemotherapy, molecular genetics, molecular medicine |
| Goods and Services | Genetic testing apparatus for medical purposes; diagnostic equipment and instruments for medical purposes for the analysis of body fluids, benign and malignant tissue and blood, protein structures of tumors, genetic code of tissue and blood cells, analysis of blood cells, blood plasma and blood serum; medical apparatus for carrying-out diagnostic tests for medical purposes for cancer cells, leukemia cells, benign and malignant cells of humans and animals, genetic material; medical testing instruments for medical diagnostic purposes for blood sugar levels, cancer cells, genetic material; electromedical diagnostic instruments, namely, electromedical rehabilitative and pain management products for clinical and home use, namely, electrical nerve and muscle stimulators, ultrasonic stimulators, magnet therapy stimulators and laser therapy stimulators; radiation instruments, for medical purposes, namely, radiation therapy devices; medical radiation apparatus for medical purposes; medical apparatus for the treatment of cancer; apparatus for DNA and RNA testing for medical purposes; all the aforesaid goods relating to the fields of oncology, chemotherapy, molecular genetics, molecular medicine |
| Goods and Services | Scientific analysis in the field of pharmaceuticals, and medical devices; scientific research in the field of genetics, hematology, and oncology; genetic scientific research; pharmaceutical research services; clinical research in the field of radiology, radiotherapy, surgical medicine, oncological system therapy of malignant and benign diseases, and infectious diseases; research relating to biotechnology; medical research; computer aided diagnostic testing services, namely, diagnostic services for others for scientific research purposes; design and development of medical diagnostic apparatus; design and development of medical technology; development of pharmaceutical preparations and medicines; provision of information and data relating to medical and veterinary research and development; consultancy relating to research and development in the field of therapeutics; providing scientific research information in the field of medical disorders and their treatment; laboratory testing and analysis for medical research purposes in the field of bacteriology, chemistry, life science, molecular genetics, protein diagnostics, oncology, hematology, radiology, and radiotherapy; biomedical assay services and development for the analysis of body fluids, tissue samples and fluids and blood and blood products for benign and malignant diseases in the field of diagnostic preparations, implements and medication; all the aforesaid services relating to the fields of oncology, chemotherapy, molecular genetics, molecular medicine |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, June 12, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials. |
| US Class Codes | 026, 039, 044 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, June 12, 2023 |
| Primary Code | 010 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, June 12, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, June 12, 2023 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | NOT AVAILABLE |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 01 - Individual |
| Address | DE |
Trademark Events
| Event Date | Event Description |
| Thursday, June 8, 2023 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Monday, June 12, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, June 16, 2023 | APPLICATION FILING RECEIPT MAILED |
| Friday, November 3, 2023 | ASSIGNED TO EXAMINER |
| Tuesday, November 14, 2023 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Wednesday, November 15, 2023 | REFUSAL PROCESSED BY MPU |
| Monday, December 4, 2023 | REFUSAL PROCESSED BY IB |
| Tuesday, May 7, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, May 7, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, May 7, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, June 11, 2024 | FINAL REFUSAL WRITTEN |
| Tuesday, June 11, 2024 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Wednesday, November 6, 2024 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Saturday, November 23, 2024 | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB |
| Thursday, December 5, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, November 13, 2023 | NON-FINAL ACTION WRITTEN |
| Wednesday, November 15, 2023 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Tuesday, June 11, 2024 | FINAL REFUSAL E-MAILED |
| Wednesday, November 6, 2024 | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB |
| Thursday, December 5, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, December 5, 2024 | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
| Tuesday, December 10, 2024 | EXAMINER'S AMENDMENT ENTERED |
| Tuesday, December 10, 2024 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Tuesday, December 10, 2024 | EXAMINERS AMENDMENT E-MAILED |
| Tuesday, December 10, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Tuesday, December 10, 2024 | EXAMINERS AMENDMENT -WRITTEN |
